CYFRA 21-1 (LUNG CANCER MARKER)

CYFRA 21-1 (LUNG CANCER MARKER) is a specialized diagnostic laboratory test designed to measure the quantitative concentration of cytokeratin 19 fragments in a blood sample. CYFRA 21-1 is a well-established tumor marker associated primarily with non-small cell lung cancer (NSCLC), particularly squamous cell carcinoma, as well as certain other epithelial malignancies. When tumor cells proliferate or break down, cytokeratin 19 fragments are released into the bloodstream, making a CYFRA 21-1 assay a valuable tool for assisting in diagnosis, monitoring therapeutic response, and detecting recurrence in lung cancer patients.

Measurement of serum CYFRA 21-1 levels provides direct clinical insight into tumor burden, treatment efficacy, and disease progression. Because specialized tumor marker testing aids oncologists in tracking complex malignancies, blood assays supply essential clinical data for oncology, pulmonology, and internal medicine evaluations.

The test requires a simple venous blood sample collected by a qualified phlebotomist using standard collection containers, followed by precise quantitative analysis using advanced immunoassay techniques. Results must always be interpreted in conjunction with the patient's clinical history, imaging studies, biopsy findings, and symptoms.

Benefits of CYFRA 21-1 (LUNG CANCER MARKER) Testing

• Provides a direct quantitative measurement of cytokeratin 19 fragments circulating in the bloodstream.
• Helps support the evaluation and monitoring of non-small cell lung cancer (NSCLC), especially squamous cell carcinoma.
• Assists clinicians in tracking therapeutic efficacy and response to anti-cancer treatments.
• Aids in the early detection of disease recurrence or progression during post-treatment follow-up.
• Supports tracking of specialized oncological care plans.
• Complements chest imaging studies, tissue biopsies, other tumor markers (such as CEA or SCC), and comprehensive oncology panels.
• Utilizes precise laboratory immunoassay techniques for reliable results.
• Assists specialists in determining appropriate oncological and medical management strategies.
• Provides dependable turnaround times to support specialized clinical care.
• Utilizes a standard venous blood collection procedure.

Clinical Indications and Applications

Lung Cancer Monitoring: The primary clinical indication is monitoring patients diagnosed with non-small cell lung cancer to assess treatment response and detect potential recurrence.

Oncological Evaluation: The test is utilized when investigating pulmonary masses or evaluating epithelial malignancies alongside imaging and histological findings.

Why Doctors Recommend This Test

Oncologists, pulmonologists, and specialists recommend this blood test when managing lung cancer therapy, evaluating treatment efficacy, or monitoring for disease relapse. It delivers essential quantitative data required to guide safe clinical intervention.

Preparation Before the Test

Fasting is generally not required for a CYFRA 21-1 tumor marker test unless specified alongside other comprehensive laboratory evaluations. Patients should follow specific instructions provided by their doctor or the testing facility. Inform the healthcare team about all current prescriptions, previous cancer treatments, smoking history, and relevant medical history.

Wearing comfortable clothing with sleeves that can be easily rolled up will facilitate a smooth and efficient blood collection process.

What Happens During the Procedure?

The collection procedure involves a standard venous blood draw (venipuncture) performed by a skilled phlebotomist. A tourniquet is securely wrapped around the upper arm to enhance blood flow into the veins. The skin over the selected puncture site, typically inside the elbow or the back of the hand, is cleaned using an antiseptic wipe.

A sterile needle is gently inserted into the vein, and blood is collected into an evacuated collection tube or syringe. Patients may feel a brief, mild pinch or stinging sensation as the needle enters the skin. Once an adequate sample has been obtained, the needle is withdrawn, and gentle pressure is applied to the site using a clean cotton ball or gauze pad, secured with a small adhesive bandage.

The entire collection process takes only a few minutes. The labeled sample is then promptly transported to the laboratory for specialized immunoassay analysis.

Normal Reporting Time

The report for the CYFRA 21-1 (LUNG CANCER MARKER) test is generally available within 24 to 48 hours due to standard laboratory processing times. Results must be reviewed promptly with the referring oncologist or specialist.

Who Should Consider This Test?

• Patients diagnosed with non-small cell lung cancer undergoing chemotherapy, radiation, or surgical therapy.
• Individuals monitored for recurrence following successful lung cancer treatment.
• Patients evaluated for pulmonary masses or specialized oncological investigations as directed by a clinician.

Understanding Test Results

Test results provide the quantitative concentration of serum CYFRA 21-1, typically measured in nanograms per milliliter (ng/mL), evaluated against established reference thresholds.

Normal Findings: Levels falling within expected reference limits indicate low or undetectable cytokeratin 19 fragment circulation.

Elevated Findings: High CYFRA 21-1 levels suggest the presence of active lung cancer or tumor proliferation, prompting further diagnostic imaging or therapeutic review by an oncologist.

Clinical Limitations

CYFRA 21-1 is not specific solely to lung cancer; elevated levels can occasionally be observed in other benign or malignant conditions (such as renal failure, liver disease, or other epithelial cancers), requiring careful clinical correlation.

Important Safety Information

Severe respiratory distress, persistent chest pain, unexplained weight loss, or acute oncological symptoms require immediate medical attention. Patients must consult their healthcare provider or oncologist to interpret tumor marker test findings.